Although both HP and HPy are currently optional anti-HER2 targeted combinations for HER2-positive BC, there is no definitive conclusion on which regimen is superior due to the lack of prospective, randomized head-to-head comparisons between them. Here, ERBB2 is linked to breast cancer.